Mint Med logo

Mint Med Review

Best for: flat $159 all-doses compounded GLP-1 with no membership

Mint Med is a national, no-membership compounded-GLP-1 telehealth platform offering semaglutide and tirzepatide on a flat "all doses" price — avoiding the per-tier escalation common as patients titrate up. It's LegitScript Certified, HSA/FSA eligible, and cancelable anytime with 48 hours' notice. Pricing is $159/mo across 36 states, with a 175NOW promo bringing the first six weeks to $175. (Distinct from the Utah-only Mint Medical Clinic.)

By Eli Marsden · Founding Editor
Editorially reviewed (not clinically reviewed) · How we verify contentLast reviewed
7.5
★★★3.8
SemaglutideTirzepatideLegitScript VerifiedNo Membership FeeHSA/FSA Accepted36 StatesCancel Anytime
$117/mo
Same price at every dose

What the monthly price covers

Medication

Included

Provider visits

Not disclosed

Shipping

Not disclosed

Lab work

Not disclosed

Coaching

Not disclosed

See plans →

No insurance neededVetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

The Bottom Line

Mint Med is one of the most affordable GLP-1 options on the market.

Score: 7.5/10Best for: flat $159 all-doses compounded GLP-1 with no membershipFrom: $117/mo
Mint Med logo
3.8 / 5
Our editorial rating
Visit Mint Med

from $117/mo · no insurance needed

Mint Med at a glance

Type
GLP-1 telehealth provider
Medications
Semaglutide, Tirzepatide
Starting price
$117/mo
Pricing model
Flat — dose increases don't raise the monthly price
What's included
Medication
Availability
36 states
FDA status
No FDA warning letter on record

How we scored Mint Med

Each dimension is scored algorithmically from Mint Med’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.

Value25%

8.5/10

At $117/mo, Mint Med runs about 31% below the $170 median for GLP-1 providers. Pricing is flat across doses, so there is no escalation markup as you titrate up.

Effectiveness25%

7.6/10

Mint Med offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.

User Experience15%

6.7/10

Online intake and platform experience; 7 platform features disclosed.

Trust & Safety15%

8.3/10

Key details fully confirmed by our editors; no FDA warning letters on file; dispenses through an accredited compounding pharmacy (last checked 2026-06-06).

Accessibility10%

7.2/10

Mint Med is available in 36 states. FSA/HSA cards are accepted.

Support10%

5.4/10

Mint Med provides standard clinician follow-up; no extended coaching or community program is disclosed.

How we verified this Mint Med review

Last checked 2026-06-06
  • Confirmed current pricing across 3 dose/plan tiers
  • Confirmed availability in 36 states
  • Confirmed what the monthly price does and doesn't include
  • Checked the FDA warning-letter database for enforcement actions
  • Walked the public intake/checkout flow on the provider's site

Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: high.

GLP-1 medications Mint Med offers

Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.

Pricing

All doses (standard monthly)Compounded
$159/mo
semaglutide
First Six Weeks promo (code 175NOW)Compounded
$117/mo
semaglutide
All doses (standard monthly)Compounded
$159/mo
tirzepatide

Ready to get started?

Plans and promotions change often — check Mint Med's current pricing and active discounts before you decide.

See Mint Med pricing →

What we like

  • $159 flat 'all doses' pricing — no per-tier escalation as you titrate up, unlike competitors that start cheap then jump past $200
  • No membership — pay-as-you-go monthly, cancel anytime with 48-hour notice
  • LegitScript Certified with a verifiable ID
  • Publishes the FDA compounded-medication disclaimer
  • 36 states listed explicitly — strong coverage
  • HSA/FSA eligible (uncommon for compounded GLP-1)
  • Asynchronous telehealth in eligible states for faster intake; intro promo (175NOW) ≈ $117/mo for the first six weeks

Watch-outs

  • Easily confused with Mint Medical Clinic (a separate Utah-only med spa)
  • 503A/503B pharmacy partner not named, and the compounding designation isn't specified
  • Named medical director / clinical leadership not disclosed
  • Corporate legal entity not disclosed
  • Governing law, arbitration venue, and physical address not disclosed
  • Marketing says 35 states but lists 36 — minor inconsistency
  • Asynchronous model means limited live-provider interaction in eligible states

Mint Med: one flat price for every dose, no membership attached

Mint Med is a national, direct-to-consumer telehealth platform built around a single idea that makes it genuinely easy to evaluate: you pay one flat monthly price for compounded semaglutide or tirzepatide, and that price does not change as you titrate up. There's no membership, no per-tier ladder, and no subscription you have to argue your way out of. For people who have been burned by GLP-1 platforms that advertise a low starter rate and then quietly raise the bill every time the dose increases, that flat structure is the whole pitch — and it largely holds up against the record we verified.

One important housekeeping note before anything else: Mint Med (mintmed.com) is not the same company as Mint Medical Clinic, a Utah-only in-clinic med spa that we list separately. They share a name and nothing else. Mint Med is a national, online-only operation; if you landed here looking for the Utah hybrid clinic, you want a different listing.

How the pricing actually works

The model is refreshingly literal: Mint Med charges the same monthly rate whether you're on a low starter dose or a much higher maintenance dose. Many competitors structure their plans so the headline number only applies to the lowest tier, then escalate well past two hundred dollars a month as you move up — Mint Med deliberately doesn't. At roughly $117/month effective with its introductory pricing, it sits below the $170/month category median we track, and there's a first-six-weeks promotional code that drops your entry cost further. That intro rate is a teaser, so budget around the standard flat rate as your real long-term number rather than the promo figure.

  • Flat 'all doses' pricing — the monthly cost is the same on your starting dose and your maintenance dose
  • No membership fee layered on top — it's genuinely pay-as-you-go, month to month
  • A first-six-weeks promotional code lowers your initial cost before the standard rate kicks in
  • HSA/FSA eligible, which is uncommon for compounded GLP-1 platforms and can stretch your dollars further
  • Cancel anytime with 48 business hours' notice before your next order ships

The medications, and how they reach you

Mint Med offers two compounded injectables: semaglutide (the molecule in Wegovy and Ozempic) and tirzepatide (the molecule in Zepbound and Mounjaro). Both carry the same flat monthly price, so you can choose between them on clinical fit rather than cost. There's no oral version and no liraglutide. Crucially, these are compounded medications, not brand-name pens — Mint Med publishes the FDA's standard disclaimer that compounded drugs are made for individual patients and are not FDA-reviewed for safety or effectiveness, and that a valid prescription is required. That's the honest, correct framing, and we credit them for putting it on the homepage instead of burying it.

Intake runs through asynchronous telehealth in states that allow it — you complete a questionnaire and a licensed U.S.-based clinician reviews it, rather than scheduling a live video visit. That makes onboarding fast, but it's a trade-off: if you want a real-time conversation with the prescriber before starting, this isn't the model that gives it to you.

What actually sets it apart

The flat all-doses price is the real differentiator, and it's a meaningful one. GLP-1 treatment is a titration journey — you start low and climb — so a plan that holds the price steady as the dose rises is structurally friendlier than one that doesn't, even if the starting numbers look similar on day one. Stack on no membership, HSA/FSA eligibility, and a clean cancel-anytime policy, and Mint Med reads like it was designed for people who want predictable, no-strings monthly costs rather than a relationship with a subscription dashboard.

Trust and oversight: solid signals, real gaps

On the verification side, Mint Med earns a high-confidence rating, and the reasons are concrete: it's LegitScript Certified with a directly verifiable ID, it enumerates all 36 states it serves by name, it publishes the FDA compounding disclaimer verbatim, and its cancellation and pricing terms are stated in plain language on the site. There are no FDA warning letters on file. Those are strong primary signals, and they're why we trust the basics here. You can see how we weigh these factors in our scoring methodology.

That said, the transparency stops short in a few places worth knowing about. Mint Med does not name its 503A or 503B compounding pharmacy partner, doesn't disclose a named medical director or clinical leadership, and doesn't publish its corporate legal entity, governing law, arbitration venue, or a physical address. None of that is disqualifying — plenty of reputable platforms keep their pharmacy partner private — but if knowing exactly which pharmacy compounds your medication and who oversees the clinical program matters to you, you'll have to ask. There's also a tiny marketing inconsistency: the site says 35 states in one place but lists 36, which is cosmetic but the kind of sloppiness worth noticing.

Who should choose Mint Med — and who shouldn't

Choose it if you want the simplest possible cost structure: a single flat price that won't climb as your dose climbs, no membership, the freedom to cancel, and the bonus of paying with HSA/FSA funds. It's a strong fit for self-pay patients who are comfortable with compounded medication and an online-only, questionnaire-based intake.

Skip it if you specifically want brand-name Wegovy, Zepbound, Ozempic, or Mounjaro (Mint Med only does compounded), if you live outside its 36 states, or if you place a high value on a live video visit and on knowing your exact pharmacy and medical director by name before you commit. Those are reasonable dealbreakers, and Mint Med doesn't currently answer them.

Bottom line

Mint Med does one thing and does it cleanly: flat, predictable, membership-free pricing on compounded semaglutide and tirzepatide, backed by a verifiable LegitScript certification and honest FDA disclosures. The undisclosed pharmacy partner and clinical leadership keep it from being a perfect-transparency pick, and the asynchronous model won't suit everyone. But for a self-pay patient who wants a price that stays put as the dose goes up, it's a genuinely sensible, fairly priced option that sits below the category median.

Worth pricing against PeterMD ($105/month) and Try Ageless ($119/month) before you commit — both sit close to Mint Med on cost and formulation.

Ready to start with Mint Med?

Starting at $117/month. See current pricing and start your free consultation.

Alternatives to Mint Med

8.6/ 10
Verified partner

Enhance MD

Best for: lab-monitored compounded GLP-1 with mandatory video visit

★★★★4.3

Editorial score · methodology

$49/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full Enhance MD review →
8.5/ 10
Verified partner

Embody

Best for: lowest first-month entry pricing on compounded GLP-1s

★★★★4.3

Editorial score · methodology

$99/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full Embody review →
8.5/ 10
Verified partner

TrimRx

Best for: best overall value

★★★★4.3

Editorial score · methodology

$179/mo
CompoundedSemaglutide
Get StartedRead full TrimRx review →

Frequently Asked Questions

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.

Sources

The primary regulatory filings and peer-reviewed studies cited throughout this Mint Med review:

Sources & methodology — as of July 2026
  1. 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)WeightLossRankings.org.
  2. 2.FDA — Compounding and the 503A Pharmacy FrameworkU.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)U.S. Food & Drug Administration.
  4. 4.PCAB — Pharmacy Compounding Accreditation Board StandardsAccreditation Commission for Health Care (ACHC) / PCAB.
  5. 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)Kaiser Family Foundation.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)New England Journal of Medicine.PMID: 33567185.
  7. 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDAU.S. Food & Drug Administration.
  8. 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDAU.S. Food & Drug Administration.
  9. 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)New England Journal of Medicine.PMID: 35658024.
  10. 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDAU.S. Food & Drug Administration.
  11. 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDAU.S. Food & Drug Administration.
  12. 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)New England Journal of Medicine.PMID: 40334173.

Ready to start with Mint Med?

Starting at $117/month. See current pricing and start your free consultation.